Our Pricing

Mounjaro vs Wegovy: Which Shows Better UK Results?

When comparing mounjaro vs wegovy uk results, clinical trial data reveals significant differences in weight loss outcomes. Both medications are licensed by the MHRA for weight management in the UK, but tirzepatide (Mounjaro) demonstrated superior efficacy in head-to-head studies, with patients achieving an average 22.5% body weight reduction compared to 15% with semaglutide (Wegovy) over 72 weeks [1][2]. At Cured Pharmacy, our UK-registered clinical team helps patients access both treatments through a free online consultation, with transparent upfront pricing and discreet next-day delivery across the UK.

Clinical Trial Results: Mounjaro vs Wegovy UK Evidence

The SURPASS-2 trial provided direct comparison data between tirzepatide and semaglutide in over 1,800 patients with type 2 diabetes [1]. Participants receiving the highest dose of Mounjaro (15mg) achieved an average weight loss of 11.2kg, whilst those on Wegovy 1mg lost an average of 6.2kg over 40 weeks — a statistically significant difference that persisted throughout the study period.

In the obesity-focused SURMOUNT-1 trial, Mounjaro demonstrated even more impressive outcomes in patients without diabetes [3]. At 72 weeks, participants on the 15mg dose achieved a mean body weight reduction of 22.5%, with 63% of patients losing at least 20% of their starting weight. By comparison, the STEP trials evaluating Wegovy showed a mean weight loss of 15% at 68 weeks — substantial results, but notably lower than tirzepatide's performance [2].

These UK-licensed medications work through different mechanisms. Mounjaro is a dual GIP/GLP-1 receptor agonist, activating two incretin pathways simultaneously, whilst Wegovy targets only the GLP-1 receptor [1]. This dual action appears to enhance both glucose regulation and appetite suppression, contributing to the superior weight loss outcomes observed in clinical trials. Both treatments require prescription from a UK-registered prescriber following clinical assessment.

How Mounjaro and Wegovy Work: Mechanism Differences

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a natural hormone your gut releases after eating [2]. This hormone signals to your brain that you're full, slows stomach emptying, and improves insulin secretion. The result is reduced appetite and better blood sugar control, leading to gradual weight loss when combined with lifestyle modifications.

Mounjaro contains tirzepatide, the first dual-action medication licensed in the UK that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors [1]. The addition of GIP receptor activation appears to enhance fat metabolism and energy expenditure beyond what GLP-1 agonism achieves alone. In metabolic studies, this dual mechanism produced greater reductions in body fat percentage and visceral adipose tissue compared to semaglutide monotherapy [3].

Both medications are administered as once-weekly subcutaneous injections using pre-filled pens. The dosing schedules differ slightly: Wegovy follows a fixed escalation protocol starting at 0.25mg and increasing to a maintenance dose of 2.4mg, whilst Mounjaro begins at 2.5mg and can be titrated up to 15mg based on individual response and tolerability [4]. Your UK prescriber will determine the appropriate starting dose and escalation schedule during your clinical consultation at Cured Pharmacy.

Which Mechanism Suits Your Needs?

The choice between these mechanisms depends on your medical history, weight loss goals, and how you respond to treatment. Patients who haven't achieved adequate results with single-pathway GLP-1 medications may benefit from Mounjaro's dual-receptor approach, though this requires clinical assessment. Our UK-registered prescribers evaluate factors including your BMI, previous weight loss attempts, cardiovascular risk factors, and any contraindications before recommending the most appropriate treatment. All prescription decisions are made on an individual basis following NICE guidance for weight management interventions.

Side Effects Profile: Mounjaro vs Wegovy Tolerability

Both medications share a similar side effect profile, with gastrointestinal symptoms being the most commonly reported adverse events in clinical trials [1][2]. Nausea, diarrhoea, vomiting, constipation, and abdominal discomfort typically occur during dose escalation and tend to diminish over time as your body adjusts to treatment.

In the SURPASS trials, approximately 17% of Mounjaro patients experienced nausea at the highest dose, compared to 20% of Wegovy patients in the STEP trials [1][2]. Discontinuation rates due to adverse events were comparable: 6.2% for tirzepatide and 7.0% for semaglutide in their respective obesity trials. Most patients who experienced side effects found them manageable with dietary adjustments, such as eating smaller meals and avoiding high-fat foods.

Serious adverse events are rare but include potential risks of pancreatitis, gallbladder disease, and thyroid C-cell tumours (observed in animal studies but not confirmed in humans) [4]. Both medications carry a boxed warning regarding thyroid tumours and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Your UK prescriber will screen for these contraindications during your clinical assessment before prescribing either medication.

Managing Side Effects Effectively

Our clinical team at Cured Pharmacy provides detailed guidance on minimising side effects when you start treatment. Practical strategies include staying well-hydrated, eating slowly, choosing bland foods during the initial weeks, and avoiding lying down immediately after meals. If you experience persistent nausea or vomiting that interferes with daily activities, your prescriber may adjust your dose escalation schedule or recommend anti-nausea medication. Always report severe abdominal pain, persistent vomiting, or signs of pancreatitis to your healthcare provider immediately.

Cost Comparison: Mounjaro vs Wegovy UK Pricing

At Cured Pharmacy, Mounjaro is available from £124.99 per month, whilst Wegovy starts from £135.00 per month, with final costs depending on your prescribed dose [5]. These prices include your medication, free clinical consultation with a UK-registered prescriber, and discreet delivery to your address. We display all pricing upfront before you begin your consultation — no hidden fees or surprise charges at checkout.

The price difference reflects several factors, including the medications' manufacturing costs, licensing arrangements, and current UK market supply. Mounjaro is a newer medication with dual-receptor technology, whilst Wegovy has been available longer and benefits from established production scale. Despite the cost difference, many patients find Mounjaro's enhanced efficacy justifies the additional investment, particularly if previous weight loss attempts have been unsuccessful.

Both treatments represent a significant financial commitment compared to older weight loss medications like Orlistat or Saxenda. However, clinical trial data suggests that the substantial weight loss achieved with these GLP-1 medications may reduce long-term healthcare costs associated with obesity-related conditions such as type 2 diabetes, cardiovascular disease, and joint problems [3]. Your prescriber will discuss whether the potential benefits justify the cost based on your individual circumstances and weight loss goals.

Eligibility Criteria: Who Can Use Mounjaro vs Wegovy in the UK

NICE guidelines recommend GLP-1 receptor agonists for weight management in adults with a BMI of 35 kg/m² or higher, or 32.5 kg/m² or higher for people from Black, Asian, or other minority ethnic backgrounds [4]. Patients with a BMI of 30 kg/m² or higher may be considered if they have weight-related comorbidities such as prediabetes, type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease.

Both Mounjaro and Wegovy are contraindicated in patients with a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, or previous serious hypersensitivity reactions to tirzepatide or semaglutide [4]. They should be used with caution in patients with a history of pancreatitis, severe gastrointestinal disease, diabetic retinopathy, or renal impairment. Pregnant or breastfeeding women cannot use these medications, and women of childbearing potential should use effective contraception during treatment.

At Cured Pharmacy, our UK-registered prescribers conduct a thorough clinical assessment before prescribing either medication. You'll complete a detailed medical questionnaire covering your weight history, previous weight loss attempts, current medications, and relevant health conditions. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), oversees all clinical decisions to ensure treatments are prescribed safely and appropriately according to MHRA and NICE guidance. The entire consultation process takes under three minutes and is completely free, with no obligation to proceed if the medication isn't suitable for you.

Assessment Process at Cured Pharmacy

Your online consultation includes questions about your height, weight, medical history, current medications, and weight loss goals. Our prescribers review your responses within hours and may request additional information if needed. If approved, your prescription is sent directly to our UK-registered pharmacy, and your medication is dispensed and dispatched the same day for next-day delivery. If either Mounjaro or Wegovy isn't suitable, your prescriber will explain why and may suggest alternative treatments from our weight loss range, including Saxenda or Orlistat, depending on your clinical profile.

Long-Term Results: Maintaining Weight Loss with Mounjaro vs Wegovy

Clinical trial data extending beyond one year demonstrates that weight loss plateaus typically occur around 60-72 weeks with both medications, after which patients maintain their reduced weight as long as they continue treatment [2][3]. In the STEP-5 trial extension, Wegovy patients maintained an average 15.2% weight loss at 104 weeks, whilst SURMOUNT-1 participants on Mounjaro maintained 22.5% weight reduction at 72 weeks with ongoing therapy.

Discontinuation studies reveal a critical finding: most patients regain a significant portion of lost weight after stopping treatment [2]. In the STEP-4 withdrawal trial, participants who switched from semaglutide to placebo regained approximately two-thirds of their lost weight within one year. This suggests these medications work best as long-term treatments rather than short-term interventions, requiring ongoing commitment and lifestyle modifications to sustain results.

The most successful outcomes occur when GLP-1 medications are combined with dietary changes, increased physical activity, and behavioural support [4]. NICE recommends that pharmacological weight management should be part of a comprehensive programme including nutritional counselling and exercise guidance. At Cured Pharmacy, we provide ongoing support through our clinical team, with regular check-ins to monitor your progress, adjust dosing if needed, and address any concerns that arise during treatment. Our goal is to help you achieve sustainable weight loss that improves your overall health and quality of life.

Lifestyle Modifications for Optimal Results

Both Mounjaro and Wegovy work most effectively when combined with a reduced-calorie diet and increased physical activity. Our clinical team recommends aiming for a 500-750 calorie daily deficit through a combination of dietary changes and exercise. Focus on nutrient-dense whole foods, adequate protein intake to preserve muscle mass during weight loss, and regular movement that you enjoy and can sustain long-term. Your prescriber can provide personalised guidance based on your current activity level and any physical limitations. Remember that these medications are tools to support your weight loss journey, not replacements for healthy lifestyle habits.

Scientific References

1. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
4. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. Technology appraisal guidance [TA875]. https://www.nice.org.uk/guidance/ta875
5. Medicines and Healthcare products Regulatory Agency. (2024). Mounjaro 2.5 mg solution for injection in pre-filled pen. Summary of Product Characteristics. https://products.mhra.gov.uk/

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence to treatment, dietary modifications, and physical activity levels.